Literature DB >> 23826668

Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement.

Samantha Drennan1, Nicholas D Stafford, John Greenman, Victoria L Green.   

Abstract

The presence of regulatory T (Treg) cells is thought to be an important mechanism by which head and neck squamous cell carcinoma (HNSCC) successfully evades the immune system. Using multicolour flow cytometry, the frequency and functional capacity of two CD4(+)  CD127(low/-) Treg cell populations, separated on the basis of different levels of CD25 expression (CD25(inter) and CD25(high) ), from the peripheral circulation of newly presenting HNSCC patients were assessed with regard to clinicopathological features and healthy controls. The frequency of circulating Treg cells was similar between HNSCC patients and healthy controls, and for patients with HNSCC developing from different subsites (laryngeal compared with oropharyngeal). However, patients with advanced stage tumours and those with nodal involvement had significantly elevated levels of CD4(+)  CD25(high)  CD127(low/-) Treg cells compared with patients who had early stage tumours (P = 0·03) and those without nodal involvement (P = 0·03), respectively. CD4(+)  CD25(high)  CD127(low/-) Treg cells from the entire HNSCC patient cohort and from patients whose tumours had metastasized to the lymph nodes were also shown to suppress the proliferation of effector T cells significantly more, compared with those from healthy controls (P = 0·04) or patients with no nodal involvement (P = 0·04). Additionally, CD4(+)  CD25(inter)  CD127(low/-) Treg cells consistently induced greater suppressive activity than CD4(+)  CD25(high)  CD127(low/-) Treg cells on the proliferation of the effector T-cell populations (CD4(+)  CD25(-)  CD127(-/+) and CD4(+)  CD25(+)  CD127(+) ). Peripheral Treg cells, identified by the CD127(low/-) phenotype, have been shown to be influenced by a patient's tumour stage and/or nodal status in HNSCC; suggesting a role in tumour progression that could be manipulated by future immunotherapy.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD127low/−; head and neck squamous cell carcinoma; regulatory T cells; suppression

Mesh:

Substances:

Year:  2013        PMID: 23826668      PMCID: PMC3800438          DOI: 10.1111/imm.12144

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

1.  Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma.

Authors:  L J Chi; H T Lu; G L Li; X M Wang; Y Su; W H Xu; B Z Shen
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

2.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 4.  Protective mechanisms of head and neck squamous cell carcinomas from immune assault.

Authors:  M Rita I Young
Journal:  Head Neck       Date:  2006-05       Impact factor: 3.147

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.

Authors:  Junko Yokokawa; Vittore Cereda; Cinzia Remondo; James L Gulley; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

7.  Molecular mechanisms of treg-mediated T cell suppression.

Authors:  Angelika Schmidt; Nina Oberle; Peter H Krammer
Journal:  Front Immunol       Date:  2012-03-21       Impact factor: 7.561

Review 8.  Immune suppression in head and neck cancers: a review.

Authors:  Anaëlle Duray; Stéphanie Demoulin; Pascale Hubert; Philippe Delvenne; Sven Saussez
Journal:  Clin Dev Immunol       Date:  2011-03-10

9.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

10.  Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.

Authors:  M K Levings; R Sangregorio; M G Roncarolo
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

View more
  23 in total

Review 1.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

2.  Frequently Increased but Functionally Impaired CD4+CD25+ Regulatory T Cells in Patients with Oral Lichen Planus.

Authors:  Leilei Zhou; Tianyi Cao; Yufeng Wang; Hui Yao; Guanhuan Du; Guangjie Chen; Xiaoyin Niu; Guoyao Tang
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

3.  Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.

Authors:  Martin Grimm; Oliver Feyen; Heiko Hofmann; Peter Teriete; Thorsten Biegner; Adelheid Munz; Siegmar Reinert
Journal:  Tumour Biol       Date:  2015-10-16

Review 4.  Immunomethylomics: A Novel Cancer Risk Prediction Tool.

Authors:  Karl T Kelsey; John K Wiencke
Journal:  Ann Am Thorac Soc       Date:  2018-04

5.  Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity.

Authors:  Abigail E Overacre-Delgoffe; Maria Chikina; Rebekah E Dadey; Hiroshi Yano; Erin A Brunazzi; Gulidanna Shayan; William Horne; Jessica M Moskovitz; Jay K Kolls; Cindy Sander; Yongli Shuai; Daniel P Normolle; John M Kirkwood; Robert L Ferris; Greg M Delgoffe; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Cell       Date:  2017-05-25       Impact factor: 41.582

6.  Differential expression of Helios, Neuropilin-1 and FoxP3 in head and neck squamous cell carcinoma (HNSCC) patients.

Authors:  A A Mohamed Adil; Anil Kumar Bommanabonia; Anandraj Vaithy; Sateesh Kumar; Mohammad Waseem; Shazia Jamal; Neesar Ahmed
Journal:  3 Biotech       Date:  2019-04-16       Impact factor: 2.406

7.  Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.

Authors:  Donald T Weed; Paolo Serafini; Jennifer L Vella; Isildinha M Reis; Adriana C De la Fuente; Carmen Gomez; Zoukaa Sargi; Ronen Nazarian; Joseph Califano; Ivan Borrello
Journal:  Clin Cancer Res       Date:  2014-10-15       Impact factor: 12.531

8.  Investigation of immune cell markers in feline oral squamous cell carcinoma.

Authors:  Ellen E Sparger; Brian G Murphy; Farina Mustaffa Kamal; Boaz Arzi; Diane Naydan; Chrisoula T Skouritakis; Darren P Cox; Katherine Skorupski
Journal:  Vet Immunol Immunopathol       Date:  2018-06-13       Impact factor: 2.046

9.  Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.

Authors:  Baodan Yu; Junli Wang; Chen He; Wei Wang; Jianli Tang; Runhui Zheng; Chengzhi Zhou; Huanhuan Zhang; Zhiping Fu; Qiasheng Li; Jun Xu
Journal:  Exp Ther Med       Date:  2017-06-08       Impact factor: 2.447

10.  Cytokine and Adipokine Levels in Patients with Premalignant Oral Lesions or in Patients with Oral Cancer Who Did or Did Not Receive 1α,25-Dihydroxyvitamin D3 Treatment upon Cancer Diagnosis.

Authors:  M Rita I Young; Corinne Levingston; Sara D Johnson
Journal:  Cancers (Basel)       Date:  2015-06-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.